trending Market Intelligence /marketintelligence/en/news-insights/trending/wushtof-gagt-swn4qdbmq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Innovus secures rights to allergy drug in US, Canada

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Innovus secures rights to allergy drug in US, Canada

Innovus Pharmaceuticals Inc. secured a contract to market NTC Srl's Lertal tablets in U.S. and Canada under the AllerVarx brand name.

Innovus is making an undisclosed up-front payment to the Italian company and has agreed to make further milestone-related payments as a result of the agreement.

Lertal is used for the treatment of allergic rhinitis.